Sarbajit Mukherjee
Overview
Explore the profile of Sarbajit Mukherjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu G, Liu S, Wang S, Zheng J, Wang Y, Wang H, et al.
J Thorac Dis
. 2025 Feb;
17(1):441-449.
PMID: 39975753
Background: Camrelizumab combined with chemotherapy has shown significant clinical benefits in the first-line treatment of advanced esophageal squamous cell cancer (ESCC). Despite promising results from randomized trials, there is a...
2.
Mukherjee S, Pattnaik H, Sonti S, Ramesh M, Jain P, Ramirez R, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858006
Background: Neuroendocrine carcinomas (NECs) are treated with a frontline platinum-etoposide combination with no standard second-line therapies. We explored a novel combination of nanoliposomal irinotecan (Nal-IRI), 5-fluorouracil (5-FU), and leucovorin (LV)...
3.
Farrugia M, Repasky E, Chen M, Attwood K, Catalfamo K, Rosenheck H, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):57.
PMID: 39751903
Background: Esophageal cancer (ESC) is an aggressive disease which often presents at an advanced stage. Despite trimodal therapy, 40-50% patients can develop metastatic disease by 18 months. Identification of patients...
4.
Bawek S, Mukherjee S
Transl Gastroenterol Hepatol
. 2024 Nov;
9:55.
PMID: 39503042
No abstract available.
5.
Vadehra D, Sonti S, Siromoni B, Ramesh M, Mukhopadhyay D, Groman A, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457723
Background/objectives: Recent epidemiological studies have revealed an upward trend in young-onset colorectal cancer (YOCRC) overall, whereas specific data on young-onset colorectal neuroendocrine neoplasms (YONEN) remain limited. This study investigated the...
6.
Bawek S, Ramesh M, Gurusinghe S, Aijaz A, Attwood K, Hossein-Javaheri N, et al.
JNCI Cancer Spectr
. 2024 Oct;
8(6).
PMID: 39436987
The role of immune checkpoint inhibitors for patients with gastroesophageal cancer with liver metastasis remains unclear. Our objective was to investigate whether immune checkpoint inhibitors are beneficial in patients with...
7.
Boland P, Mukherjee S, Imanirad I, Vijayvergia N, Cohen S, Gupta M, et al.
Br J Cancer
. 2024 Sep;
131(8):1290-1297.
PMID: 39244627
Background: The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited. TAS-102 is a novel oral antimetabolite with a distinct mechanism...
8.
Kalvapudi S, Pachimatla A, Seager R, Conroy J, Pabla S, Mukherjee S
Med Oncol
. 2024 Aug;
41(9):227.
PMID: 39143271
Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets due to their high...
9.
Gupta K, Roy A, Attwood K, Nipp R, Mukherjee S
Healthcare (Basel)
. 2024 Aug;
12(15).
PMID: 39120199
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, with increasing data demonstrating improved survival outcomes using ICIs among patients with advanced gastroesophageal cancer (GEC). ICIs are also associated with...
10.
Kalvapudi S, Pachimatla A, Seager R, Conroy J, Pabla S, Mukherjee S
Res Sq
. 2024 Jul;
PMID: 38947068
Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets due to their high...